Establishing risk of human experimentation with drugs: lessons from TGN1412

Particular care is necessary when a new drug is given to healthy volunteers without previous human testing. General principles for such research have been laid down in guidelines as early as 1983, and these were the basis for many current regulations. 2 Most drugs at that time were small molecules with fairly well characterised, classic, pharmacological mechanisms. Proposed primary objectives for studies in healthy people were therefore to show pharmacological action in man and the dose (or concentration) response curve. This approach was judged safe and was lent support by fi ndings of available surveys. 3,4

[1]  S. Chattopadhyay,et al.  CD28 signaling in neutrophil induces T-cell chemotactic factor(s) modulating T-cell response. , 2003, Human immunology.

[2]  P. W. Willis,et al.  Clinically significant adverse effects in a Phase 1 testing program , 1978, Clinical pharmacology and therapeutics.

[3]  C. Lewis,et al.  Differential effects of LPS, IFN-gamma and TNF alpha on the secretion of lysozyme by individual human mononuclear phagocytes: relationship to cell maturity. , 1990, Immunology.

[4]  Robert Riddell,et al.  Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. , 2005, The New England journal of medicine.

[5]  L. Chess,et al.  Regulation of immune responses by T cells. , 2006, The New England journal of medicine.

[6]  A. Feldman,et al.  Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  A. Heath,et al.  Co-stimulatory agonists as immunological adjuvants. , 2006, Vaccine.

[8]  T. Gooley,et al.  Non-Fc Receptor-Binding Humanized Anti-CD3 Antibodies Induce Apoptosis of Activated Human T Cells1 , 2000, The Journal of Immunology.

[9]  Robert Combes,et al.  TGN1412: Time to Change the Paradigm for the Testing of New Pharmaceuticals , 2006, Alternatives to laboratory animals : ATLA.

[10]  Thomas A. Davis,et al.  Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[11]  T. Hanke,et al.  Topological Requirements and Signaling Properties of T Cell–activating, Anti-CD28 Antibody Superagonists , 2003, The Journal of experimental medicine.

[12]  J. Löwer,et al.  TGN1412—a regulator's perspective , 2006, Nature Biotechnology.

[13]  P. Routledge,et al.  Healthy volunteer studies in Great Britain: the results of a survey into 12 months activity in this field. , 1989, British journal of clinical pharmacology.

[14]  T. Hanke,et al.  Transient accumulation of human mature thymocytes and regulatory T cells with CD28 superagonist in "human immune system" Rag2(-/-)gammac(-/-) mice. , 2006, Blood.

[15]  I. H. Carmen.  A death in the laboratory: the politics of the Gelsinger aftermath. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[16]  D. Stuart,et al.  Crystal structure of a soluble CD28-Fab complex , 2005, Nature Immunology.

[17]  R. Steinbrook.  Protecting research subjects--the crisis at Johns Hopkins. , 2002, The New England journal of medicine.

[18]  M. Wadman.  London's disastrous drug trial has serious side effects for research , 2006, Nature.

[19]  C. Anasetti,et al.  Non-FcR-binding, humanized anti-CD3 antibody Hu291 induces apoptosis of human T cells more effectively than OKT3 and is immunosuppressive in vivo. , 2000, Transplantation proceedings.

[20]  R. Bhadra,et al.  Immunobiology of CD28 expression on human neutrophils. I. CD28 regulates neutrophil migration by modulating CXCR‐1 expression , 2001, European journal of immunology.

[21]  S. Rosenberg,et al.  Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. , 2005, Journal of immunotherapy.

[22]  Lawrence S. Chan,et al.  Human Immune System , 2003 .

[23]  J. Bluestone,et al.  T cell inactivation and cytokine deviation promoted by anti-CD3 mAbs. , 1997, Current opinion in immunology.

[24]  M. Gordon.  Enterocolitis in Patients With Cancer After Antibody Blockade of Cytotoxic T-Lymphocyte–Associated Antigen 4 , 2008 .